Evidence map›Paper›PMID 41729308›Full record

ArticleAnnals of hematology2026

Long-term outcome of children with acute lymphoblastic leukemia after hematopoietic stem cell transplantation based on ex-vivo alpha-beta T cell depletion.

Larisa Shelikhova, Maria Ilyushina, Rimma Khismatullina, Dmitriy Balashov, Sergey Blagov, Irina Shipitsina, Svetlana Kozlovskaya, Olga Molostova, Yulia Abugova, Alexey Kazachenok and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Larisa ShelikhovaBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia. lnik1976@mail.ru.
Maria IlyushinaBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Rimma KhismatullinaBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Dmitriy BalashovBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Sergey BlagovBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Irina ShipitsinaBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Svetlana KozlovskayaBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Olga MolostovaBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Yulia AbugovaBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Alexey KazachenokBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Yakov MuzalevskyBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Elena KurnikovaBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Kirill VoroninBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Pavel TrakhtmanBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Maria KlimentovaBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Daria KobyzevaBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Dmitriy PershinBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Yulia OlshanskayaBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Alexey NechesnyukBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Alexander PopovBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Natalia MyakovaBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Dmitriy LitvinovBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Galina NovichkovaBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Alexander KarachunskiyBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Alexey MaschanBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.
Michael MaschanBMT Department, Dmitry Rogachev Federal Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, RF, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematopoietic stem cell transplantation (HSCT) is a curative option for children with high-risk acute lymphoblastic leukemia (ALL). This retrospective single-center study analyzed 236 pediatric ALL patients in complete remission who underwent allogeneic HSCT using ex-vivo T cell depletion between 2012 and 2021. The majority received haploidentical grafts (n = 202), while the remainder received matched unrelated donor (MUD) grafts (n = 34). At four years, event-free survival (EFS) and overall survival (OS) were 57% and 67%, respectively. Total body irradiation (TBI)-based conditioning was associated with significantly lower relapse rates and superior EFS compared to chemotherapy-based regimens. Non-relapse mortality (NRM) was low (9%), with no significant difference between donor types. Pre-transplant minimal residual disease (MRD) positivity and transplantation beyond first complete remission were independently associated with higher relapse and inferior survival. Chronic GVHD incidence was lower in patients receiving abatacept and tocilizumab instead of ATG. These findings confirm the safety and efficacy of ex-vivo T cell-depleted HSCT in pediatric ALL, with outcomes comparable between haploidentical and MUD donors. TBI-based conditioning and MRD negativity remain key prognostic factors for improved outcome.

Indexed as

Hematopoietic Stem Cell TransplantationLymphocyte DepletionPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Antigen, T-Cell, alpha-betaT-LymphocytesAdolescentChildChild, PreschoolDisease-Free SurvivalFemaleGraft vs Host DiseaseHumansInfantMaleNeoplasm, ResidualRetrospective StudiesReceptors, Antigen, T-Cell, alpha-betaAcute lymphoblastic leukemiaAllogeneic HSCTHSCTLong-term follow-upPediatricT cell-depleted

Identifiers

PMID41729308
PMCPMC12929346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.